| scholarly article | Q13442814 |
| P50 | author | Alberto Floris | Q57569408 |
| Alberto Cauli | Q112551656 | ||
| Alessandro Mathieu | Q114314184 | ||
| Matteo Piga | Q37829183 | ||
| Carlo Salvarani | Q37835033 | ||
| P2860 | cites work | Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. | Q50590140 |
| Pathogenesis of polymyalgia rheumatica. | Q52339672 | ||
| Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. | Q64892284 | ||
| Patterns of disease activity in systemic lupus erythematosus | Q73313572 | ||
| Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus | Q79171865 | ||
| Interleukin-1RN gene polymorphisms in elderly patients with rheumatic inflammatory chronic conditions: Association of IL-1RN*2/2 genotype with polymyalgia rheumatica | Q82695198 | ||
| Polymyalgia rheumatica | Q88678153 | ||
| A proposed classification of the immunological diseases | Q21144701 | ||
| Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis | Q24674760 | ||
| Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica | Q24805430 | ||
| Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review | Q30249624 | ||
| Defining the role of the MHC in autoimmunity: a review and pooled analysis | Q33330857 | ||
| The epidemiology of autoimmune diseases | Q34212462 | ||
| EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. | Q34844578 | ||
| Are polymyalgia rheumatica and giant cell arteritis the same disease? | Q35744074 | ||
| Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study | Q37156399 | ||
| Autoimmune diseases induced by biological agents: a double-edged sword? | Q37620986 | ||
| Autoinflammation and autoimmunity: bridging the divide. | Q38033406 | ||
| Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives | Q38033875 | ||
| Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases | Q38058508 | ||
| Update on polymyalgia rheumatica | Q38098373 | ||
| Recommendations for the management of autoinflammatory diseases. | Q38537504 | ||
| Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review | Q38752671 | ||
| Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers | Q40171678 | ||
| Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica | Q41459888 | ||
| Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. | Q43985376 | ||
| Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study | Q45254662 | ||
| Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease | Q46320173 | ||
| Autoimmune-autoinflammatory rheumatoid arthritis overlaps: a rare but potentially important subgroup of diseases | Q47148331 | ||
| P433 | issue | 1 | |
| P921 | main subject | polymyalgia rheumatica | Q1752891 |
| P304 | page(s) | e000694 | |
| P577 | publication date | 2018-06-04 | |
| P1433 | published in | RMD open | Q27726913 |
| P1476 | title | Polymyalgia rheumatica: an autoinflammatory disorder? | |
| P478 | volume | 4 |
| Q59329872 | Comorbidities in polymyalgia rheumatica: a systematic review | cites work | P2860 |
Search more.